6-K: Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Published on May 28, 2015
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
|
For the month of: May 2015
|
|
Commission File Number: 001-35776
|
ACASTI PHARMA INC.
(Name of Registrant)
545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s Registration Statements on Form F-10 (File No. 333-191907) and Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ACASTI PHARMA INC.
|
||
|
Date: May 27, 2015
|
By:
|
a/s/ Pierre Lemieux
|
|
Name: Pierre Lemieux
Title: Chief Operating Officer
|
EXHIBIT INDEX
|
Exhibit
|
Description of Exhibit
|
|
99.1
|
Management Discussion and Analysis of Financial Condition and Results of Operations of Acasti Pharma Inc. for fiscal years ended February 28, 2015, 2014 and 2013.
|
|
99.2
|
Audited Financial Statements of Acasti Pharma Inc. as at February 28, 2015 and 2014 and for each of the years in the three-year period ended February 28, 2015, together with the notes thereto.
|
|
99.3
|
Acasti Annual Information Form Year Ended February 28, 2015
|
|
99.4
|
Consent of KPMG LLP.
|